Takeda Submits Application For Insomnia Drug Remelteon In Japan
This article was originally published in PharmAsia News
On Feb. 29, Takeda applied for approval for sleeping pill remelteon (TAK-375) with Japan's Ministry of Health, Labor and Welfare. Remelteon works by selectively targeting two melatonin receptors in the brain, MT1 and MT2. By acting on these receptors, the body's sleep-wake cycle is regulated and physiological sleep is promoted. Because it did not show evidence for potential abuse or dependence in clinical studies, remelteon is the first insomnia medication not regulated by the U.S. Drug Enforcement Administration. Approved by the U.S. FDA in 2005, remelteon is marketed under the brand name Rozerem. Takeda also applied for approval with the European Medicines Agency in March 2007. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.